Karuna Schizophrenia Drug Has Blockbuster Potential, Says Stifel
May 31, 2020 at 14:41 PM EDT
The full Phase 2 data for KarXT, presented over the weekend by Karuna Therapeutics, show a schizophrenia drug that is at least as effective as the standard-of-care but via a totally new mechanism and has a "much improved" tolerability profile.
